CA2865132A1 - Compositions and methods for ocular delivery of a therapeutic agent - Google Patents

Compositions and methods for ocular delivery of a therapeutic agent Download PDF

Info

Publication number
CA2865132A1
CA2865132A1 CA2865132A CA2865132A CA2865132A1 CA 2865132 A1 CA2865132 A1 CA 2865132A1 CA 2865132 A CA2865132 A CA 2865132A CA 2865132 A CA2865132 A CA 2865132A CA 2865132 A1 CA2865132 A1 CA 2865132A1
Authority
CA
Canada
Prior art keywords
silk
therapeutic agent
composition
silk matrix
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2865132A
Other languages
English (en)
French (fr)
Inventor
David L. Kaplan
Michael L. Lovett
Xiaoqin Wang
Tuna Yucel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of CA2865132A1 publication Critical patent/CA2865132A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2865132A 2012-02-22 2013-02-22 Compositions and methods for ocular delivery of a therapeutic agent Abandoned CA2865132A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601924P 2012-02-22 2012-02-22
US61/601,924 2012-02-22
PCT/US2013/027465 WO2013126799A1 (en) 2012-02-22 2013-02-22 Compositions and methods for ocular delivery of a therapeutic agent

Publications (1)

Publication Number Publication Date
CA2865132A1 true CA2865132A1 (en) 2013-08-29

Family

ID=49006267

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865132A Abandoned CA2865132A1 (en) 2012-02-22 2013-02-22 Compositions and methods for ocular delivery of a therapeutic agent

Country Status (6)

Country Link
US (2) US20150037422A1 (https=)
EP (1) EP2817031A4 (https=)
JP (1) JP2015508104A (https=)
CA (1) CA2865132A1 (https=)
HK (1) HK1205461A1 (https=)
WO (1) WO2013126799A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105169476A (zh) * 2015-09-15 2015-12-23 王岩松 一种医用原位凝胶的制备方法及其应用
US12350261B2 (en) 2012-11-08 2025-07-08 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939952C (en) 2013-03-05 2022-03-22 Morgan V. Fedorchak Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery
PL2968650T3 (pl) 2013-03-14 2019-05-31 Panoptica Inc Preparaty do oczu do dostarczania leku do tylnego fragmentu oka
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
WO2014145002A2 (en) 2013-03-15 2014-09-18 Kluge Jonathan A Low molecular weight silk compositions and stabilizing silk compositions
EP4137139A1 (en) 2013-07-10 2023-02-22 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
US20150164882A1 (en) * 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150129457A1 (en) * 2013-07-22 2015-05-14 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
CN104667287B (zh) * 2013-11-27 2018-02-06 山东博士伦福瑞达制药有限公司 用于治疗眼后房新生血管增生的眼用组合物及其用途
CN103656746A (zh) * 2013-12-13 2014-03-26 无锡合众信息科技有限公司 一种可自愈水凝胶玻璃体填充物及其制备方法
WO2015106005A1 (en) * 2014-01-08 2015-07-16 Circuit Therapeutics, Inc. Method for therapeutic management of ocular hypertension
US10010610B2 (en) * 2014-01-16 2018-07-03 Retinal Therapies, LLC Compositions and methods for the treatment of intraocular neovascularization and/or leakage
WO2015117888A1 (en) * 2014-02-04 2015-08-13 Amsilk Gmbh Coated silk films, methods for the production thereof and uses thereof
CN104027847B (zh) * 2014-06-20 2015-08-26 西安交通大学 一种附带血管网流道的人工软组织体的制造方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2781114T3 (es) 2014-08-20 2020-08-28 Silk Tech Ltd Composición proteica derivada de fibroína
ES2863601T3 (es) * 2014-09-17 2021-10-11 Panoptica Inc Formulaciones oculares para administración de fármacos y protección del segmento anterior del ojo
CN104368046B (zh) * 2014-11-10 2016-01-13 四川大学 一种纤维增强型载药水凝胶人工角膜裙边支架及其制备方法
AU2015360469B2 (en) * 2014-12-10 2021-03-25 Incept, Llc Hydrogel drug delivery implants
CN104587531B (zh) * 2014-12-25 2016-05-04 南京臻泉医药科技有限公司 一种修复关节软骨损伤的凝胶支架的制备方法
US20160303281A1 (en) * 2015-04-17 2016-10-20 Rochal Industries, Llc Composition and kits for pseudoplastic microgel matrices
EP3291886A1 (en) 2015-05-04 2018-03-14 Ecole Polytechnique Federale de Lausanne (EPFL) Ophthalmic contact lens with a compressible affinity matrix
KR102643821B1 (ko) 2015-06-06 2024-03-07 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
TWI700085B (zh) 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
WO2017053686A1 (en) * 2015-09-24 2017-03-30 Massachusetts Eye And Ear Infirmary Drug delivery system and methods of use
PL3352766T3 (pl) 2015-09-24 2021-08-02 Matrix Biology Institute Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia
CN106692977A (zh) * 2015-11-11 2017-05-24 陶虎 一种蚕丝蛋白胶囊及其制备方法
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN108778330A (zh) * 2016-01-08 2018-11-09 科尼尔赛德生物医学公司 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
WO2017165449A1 (en) * 2016-03-22 2017-09-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular biologic delivery
KR20190008210A (ko) 2016-04-08 2019-01-23 코넬 유니버시티 실크 유래 단백질을 이용한 상처 치료를 증가시키는 방법
ES2972417T3 (es) 2016-05-18 2024-06-12 Sonikure Holdings Ltd Sistema de administración transescleral de fármacos mejorada por ultrasonidos
KR102657707B1 (ko) 2016-06-02 2024-04-15 에이디에스 테라퓨틱스 엘엘씨 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
US11278546B2 (en) * 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
MX2019001633A (es) 2016-08-12 2019-09-18 Silk Tech Ltd Proteina derivada de la seda para el tratamiento de la inflamacion.
CN109890964A (zh) * 2016-09-09 2019-06-14 康奈尔大学 核酸、蛋白和小分子在玻璃体囊泡体中的递送
PT3513809T (pt) 2016-09-13 2022-05-02 Kyowa Kirin Co Ltd Composição medicinal compreendendo tivozanib
WO2019055594A1 (en) 2017-09-13 2019-03-21 North Carolina State University BRUSHING ADIPOSE TISSUE INDUCED LOCALLY BY MICRO-NEEDLE STAMPS FOR THE TREATMENT OF OBESITY
WO2019094702A1 (en) * 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
CN108079431A (zh) * 2018-02-12 2018-05-29 南通纺织丝绸产业技术研究院 一种多层丝素蛋白复合针壁微针
CN108310618A (zh) * 2018-02-12 2018-07-24 南通纺织丝绸产业技术研究院 一种多层复合针壁丝素蛋白微针及其制备方法
CN108392728A (zh) * 2018-02-12 2018-08-14 南通纺织丝绸产业技术研究院 一种丝素蛋白多层复合微针及其制备方法
KR102810631B1 (ko) * 2018-02-26 2025-05-23 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 약물 전달 시스템
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
BR112020020930A2 (pt) 2018-04-11 2021-03-02 Ohio State Innovation Foundation composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit
US20200085979A1 (en) * 2018-09-11 2020-03-19 Stanley Satz Precision medicine theranostics and diagnostics a combination thereof
AU2019343188A1 (en) 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
WO2020102810A1 (en) 2018-11-16 2020-05-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive gel eye drop for ocular delivery of cysteamine
AU2020219436A1 (en) * 2019-02-08 2021-10-07 Ohio State Innovation Foundation Drug delivery compositions for ocular administration of therapeutics and methods of use thereof
MX2021010599A (es) * 2019-03-05 2021-12-10 Aerie Pharmaceuticals Inc Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares.
EP3976106A4 (en) 2019-05-31 2023-01-11 DOSE Medical Corporation BIOERODABLE POLYESTER-POLYMER IMPLANTS AND ASSOCIATED METHODS OF USE
AU2020288624B2 (en) 2019-06-04 2025-09-25 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20210127976A1 (en) * 2019-11-01 2021-05-06 Koninklijke Philips N.V. System and method for assessing preparedness for imaging procedures
EP4057941A4 (en) * 2019-11-15 2024-05-29 Silk Technologies Ltd. Stable formulations of silk-derived protein
EP3884929B1 (en) * 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
WO2021205471A1 (en) * 2020-04-06 2021-10-14 Jawaharlal Nehru Centre For Advanced Scientific Research Composition, injectable hydrogel and methods thereof
CN113440604B (zh) * 2021-06-24 2022-05-31 浙江泽瑞生物医药有限公司 一种有效抑制血糖的索马鲁肽的口服缓释片剂及其制备方法
US20240366565A1 (en) * 2021-09-09 2024-11-07 The Board Of Trustees Of The Leland Stanford Junior University Use of Verteporfin to Modulate Wound Healing After an Ocular Surgical Procedure or Ocular Injury
JP2025519378A (ja) 2022-06-07 2025-06-26 アドヴェラム バイオテクノロジーズ， インコーポレイテッド 視覚回復のためのメラノプシンバリアント
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物
CN116687840B (zh) * 2023-08-03 2023-10-20 四川省医学科学院·四川省人民医院 一种用于治疗眼部病状的凝胶制剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1505542A1 (ru) * 1988-01-13 1989-09-07 А. И. Иголкин Медицинска пипетка А.И.Иголкина дл глазных капель
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
US20040127472A1 (en) * 2002-08-05 2004-07-01 Jerdan Janice A. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
US20070026043A1 (en) * 2003-11-20 2007-02-01 Angiotech International Ag Medical devices combined with diblock copolymer compositions
WO2006078282A2 (en) * 2004-04-28 2006-07-27 Angiotech Biomaterials Corporation Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US8178656B2 (en) * 2004-06-11 2012-05-15 Trustees Of Tufts College Silk-based drug delivery system
PT2029746E (pt) * 2006-06-12 2012-10-15 Exegenics Inc D B A Opko Health Inc Composições e métodos para a inibição do sirna de angiogenese
KR20100029217A (ko) * 2007-05-29 2010-03-16 트러스티즈 오브 터프츠 칼리지 음파 처리를 이용한 실크 피브로인 겔화 방법
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
EP2421551B2 (en) * 2009-04-20 2020-07-15 Allergan, Inc. Silk fibroin hydrogels and uses thereof
US20110111031A1 (en) * 2009-04-20 2011-05-12 Guang-Liang Jiang Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof
US9603971B2 (en) * 2010-03-05 2017-03-28 Trustees Of Tufts College Silk-based ionomeric compositions
EP2558103A4 (en) * 2010-04-12 2013-09-25 R Tech Ueno Ltd PHARMACEUTICAL COMPOSITION FOR TREATING A MACULAR DERM

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12350261B2 (en) 2012-11-08 2025-07-08 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
CN105169476A (zh) * 2015-09-15 2015-12-23 王岩松 一种医用原位凝胶的制备方法及其应用
CN105169476B (zh) * 2015-09-15 2018-06-22 王岩松 一种医用原位凝胶的制备方法及其应用

Also Published As

Publication number Publication date
EP2817031A1 (en) 2014-12-31
WO2013126799A1 (en) 2013-08-29
HK1205461A1 (zh) 2015-12-18
EP2817031A4 (en) 2015-08-05
US20170173161A1 (en) 2017-06-22
US20150037422A1 (en) 2015-02-05
JP2015508104A (ja) 2015-03-16

Similar Documents

Publication Publication Date Title
US20170173161A1 (en) Compositions and methods for ocular delivery of a therapeutic agent
JP7668858B2 (ja) チロシンキナーゼ阻害剤を含む眼内インプラント
JP7636334B2 (ja) 治療物質の眼投与のための薬物送達組成物及びその使用法
KR20230097020A (ko) 활성제를 함유하는 안구 임플란트
JP2018515529A (ja) ハイドロゲルからの薬物送達
JP2015508104A5 (https=)
JP2016522250A (ja) 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
CN116710137A (zh) 用于在治疗眼部疾病的方法中使用的vegf拮抗剂
EP4028128A1 (en) Methods for treating ocular diseases
EP4251204A1 (en) Vegf antagonist for use in methods for treating ocular diseases
Everaert Evaluation of newly developed HPMC ophthalmic inserts with sustained release properties as a carrier for thermolabile therapeutics
HK40059966B (en) Ocular implant containing a tyrosine kinase inhibitor
HK40059966A (en) Ocular implant containing a tyrosine kinase inhibitor
HK40101395A (en) Ocular implant containing a tyrosine kinase inhibitor
JP2026072102A (ja) 眼疾患を治療するための方法
Chang PLGA Depots for Controlled Release of Bevacizumab.

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180222